Phase II trial of MNGX-100 for the treatment of naturally-occurring or surgically-induced menopausal syndrome.

Trial Profile

Phase II trial of MNGX-100 for the treatment of naturally-occurring or surgically-induced menopausal syndrome.

Planning
Phase of Trial: Phase II

Latest Information Update: 12 Mar 2016

At a glance

  • Drugs Filgrastim (Primary)
  • Indications Menopausal syndrome
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Most Recent Events

    • 12 Mar 2016 According to the company website, this phase II trial of MNGX-100 for the treatment of naturally-occurring or surgically-induced menopausal syndrome is anticipated to start in 2016.
    • 12 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top